Keyword: Walter Reed Army Institute of Research
Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.
PATH, Walter Reed and GSK have partnered to determine whether tweaking the regimen of Mosquirix could lead to better malaria protection.
Amid controversy over an exclusive product license, the U.S. government is backing away from its Zika vaccine contract with Sanofi.
HHS Secretary Tom Price offered some optimism about a vaccine for addiction, but experts say such it's far from reality.
A controversy over Sanofi's Zika vaccine candidate may spawn pricing limits for all treatments developed with the help of Defense Department funding.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Florida lawmakers are urging the Army to pump the brakes on its exclusive vaccine license to Sanofi.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to make a quick buck.
Sanofi got more than it bargained for when it teamed up with the U.S. Army to develop a Zika shot.